>R&D>Research Alliances

Research Alliances

In recent years, pharmaceutical discovery has come to require a combination of technologies from a number of specialized fields. While continuing to improve its own R&D capabilities, Takeda actively pursues alliances with other pharmaceutical manufacturers, biotechnology companies, universities, and other research institutions to efficiently introduce key technologies.

Research Alliances with overseas research organizations and companies

As of October 30, 2015

PartnerCountryResearch subjectSchedule
Seattle Genetics U.S. Research collaboration on Antibody-Drug Conjugate 2009/3-
Sage Bionetworks U.S. Research collaboration on discovering effective therapeutic targets for Central Nervous System (CNS) disease 2010/11-2015/6
Florida Hospital, Sanford-Burnham Medical Research Institute U.S. Research collaboration to target obesity 2010/12-
Zinfandel Pharmaceuticals U.S. Licensing agreement for Alzheimer's Disease Biomarker TOMM40 for the risk of Alzheimer's disease 2010/12-
BC Cancer Agency Canada Research collaboration to explore new drug targets based on gene analysis 2012/8-2015/8
Advinus Therapeutics Limited India Discovery collaboration to generate IND-ready compoundsfor major therapeutic areas, including Inflammation, CNS, GI and Metabolic diseases 2012/10-2015/9
Resolve Therapeutics U.S. Option to acquire Fc fusion antibody with nuclease for the treatment of Systemic Lupus Erythematosus (SLE) after completion of Phase 1b 2013/2-
Tri-Institutional Therapeutics Discovery Institute U.S. Collaboration of academic institutions and industry to more effectively develop innovative treatments and therapies 2013/10-2017/6
Trianni, Inc. U.S. Agreement for use of Trianni’s next generation transgenic mouse platform for the generation of human monoclonal antibodies against disease targets in all therapeutic areas 2014/3-
MacroGenics U.S. Collaboration to research and develop product candidates that will be directed against jointly selected pairs of molecular targets and using MacroGenics’ Dual-Affinity Re-Targeting (DART®) proprietary platform. 2014/9-
ImmunoGen, Inc. U.S. Research collaboration on Antibody-Drug Conjugate 2015/3-
Gencia LLC U.S. Collaboration to research and develop a new class of small molecules called Mitochondrial Associated Glucocorticoid Receptors (MAGR), agonists for potential use primarily in hematological and inflammatory diseases 2015/8-

Research Alliances with domestic research organizations and companies

PartnersResearch subjectSchedule
Kyoto University Research collaboration for basic and clinical research project of discovering treatments for obesity and schizophrenia based on CNS control 2011/1-2016/3
Keio University, Nigata University For the search for and functional analysis of disease-related RNA-binding proteins 2015/3-2018/3
Center for iPS Cell Research Application (CiRA), Kyoto University To develop clinical applications of iPS cells in areas such as heart failure, diabetes mellitus, neurological disorders and cancer 2015/4-2025/3
National Cancer Center of Japan The partnership to develop basic research to clinical development by promoting exchanges among researchers, physicians, and others engaged in anti-cancer drug discovery and cancer biology research 2015/4-2018/4